Loading data for RNAZ — first visit, this takes a few seconds.
TransCode Therapeutics In... (RNAZ)
NasdaqCM: RNAZ
· Precio en tiempo real · USD
2.97
-0.24 (-7.48%)
Al cierre: Aug 20, 2026, 8:00 PM
3.05
+2.69%
Fuera de horario: 5:20 PM
TransCode Therapeutics Inc. (RNAZ) Stock Price, Analysis & Data
-7.48% (1D)
No hay datos disponibles
| Precio de compra | 2.31 |
| Capitalización de mercado | 3.14M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -46.28M |
| Beta | n/a |
| EPS (TTM) | -48.28 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -4.95 |
| P/B (TTM) | 2.18 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 3.84 |
| Volumen | 44,311 |
| Volumen medio (20D) | 65,529 |
| Abierto | 3.12 |
| Anterior Cerrar | 3.21 |
| Rango del día | 2.87 - 3.21 |
| Rango de 52 semanas | 2.87 - 20.99 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising brea...
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 8, 2021
Empleados 12
Bolsa de Valores NasdaqCM
Símbolo bursátil RNAZ
Sitio web https://www.transcodetherapeutics.com
Desempeño financiero
En 2025, los ingresos de TransCode Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -34.66M, un aumento de 106.87%.
Estados financierosSorpresa de resultados
TransCode Therapeutics ha publicado sus resultados trimestrales en Apr 15, 2025:
